MedPath

An exploratory randomization study involving joining of two segments of food channel (small intestine) using either stapler alone or stapler and hand sewn technique

Phase 3
Completed
Conditions
Health Condition 1: K638- Other specified diseases of intestineHealth Condition 2: K631- Perforation of intestine (nontraumatic)
Registration Number
CTRI/2021/02/031261
Lead Sponsor
AIIMS New Delhi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

1.18 to 65 years of age both male and female

2.Patients can follow instructions and are ready for regular follow up

3. Able to provide informed and written consent

4.Indications for resection and anastomosis

a)Non-trauma elective and emergency cases with small intestine perforation or obstruction.

b)Mesenteric ischemia or strangulation: Small Intestinal obstruction with segmental ischemia or gangrene

c)Tumour: small bowel mass, Small bowel malignancy with adequate negative margin

d)Inflammatory bowel disease (Crohn’s enteritis with complications) refractory to conservative treatment or stricture not amenable to stricturoplasty

e)Entero-cutaneous fistula not amenable to closure or conservative treatment

f)Symptomatic benign disease such as Meckles diverticulum or perforated diverticulitis or intussusception of bowel needing resection and anastomosis

g)Incarcerated hernia

h)Patients with ileostomy for closure

Exclusion Criteria

1.Age < 18 years

2.Pregnancy

3.Refusal to consent or participate in the study

4.Proximal diverting ostomy creation at the time of intestinal anastomosis

5.Over-sewing of anastomotic edge or anastomotic site omentoplasty was performed

6.Anastomosis involving oesophagus, stomach, duodenum, colon and rectum

7.Not amenable for resection and anastomosis surgery based on surgeons judgement:

a)Anatomical difficulties in applying stapler

b)Active Inflammatory bowel disease where stricturoplasty was considered

c)Bowel with doubtful viability or questionable blood supply

d)Inadequate tumour margin

e)Patients on immunosuppressive drugs, post-chemotherapy or post-radiotherapy

f)Hypotension (blood pressure < 90/60 mmHg)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
• Safety: means the technical ability to provide air and water tight closure of anastomosis when procedure is performed by trained residents. <br/ ><br>• Efficacy: efficacy means the ability to prevent anastomotic failure. <br/ ><br>1.Dehiscence / leak: verified by reoperation and visualization or radiologically contrast extravasation <br/ ><br>2.Intra-abdominal abscess: identified by reoperation or radiologically present along with anastomotic dehiscence <br/ ><br>3.Entero-cutaneous fistula <br/ ><br>Timepoint: Safety: Immediately after completion of anastomoses <br/ ><br> <br/ ><br>Efficacy: within 30 post-operative days
Secondary Outcome Measures
NameTimeMethod
1.Anastomotic time <br/ ><br>2.Total Operative time <br/ ><br>3.Intraoperative blood loss <br/ ><br>4.Intraoperative blood transfusion (number of units: PRBC/FFP/Platelets) <br/ ><br>5.Surgical site infection <br/ ><br>6.Abdominal wall dehiscence <br/ ><br>7.In-hospital mortality <br/ ><br>8.Duration of postoperative hospital stay <br/ ><br>9.Duration of postoperative ICU stay <br/ ><br>10.Cost-effectivenessTimepoint: Anastomotic time: More than or equal to 1 minutes <br/ ><br>Total Operative time: More than or equal to 1 hours <br/ ><br>Intraoperative blood transfusion: More than or equal to 1 units <br/ ><br>Surgical site infection: Less than or equal to 30 days <br/ ><br>Abdominal wall dehiscence: Less than or equal to 30 days <br/ ><br> In-hospital mortality: Less than or equal to 30 days <br/ ><br>Duration of postoperative hospital stay: Less than or equal to 30 days <br/ ><br>Duration of postoperative ICU stay: Less than or equal to 30 days <br/ ><br>
© Copyright 2025. All Rights Reserved by MedPath